Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms

How to cite

Sacarny, Adam; Jacobson, Mireille; Powell, David. 2020. "Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms." AEA RCT Registry. AEARCTR-0006602. https://doi.org/10.1257/rct.6602-1.3000000000000003

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Adam Sacarny* , Mireille Jacobson , David Powell

* Primary investigator

Registry ID
AEARCTR-0006602
DOI
https://doi.org/10.1257/rct.6602-1.3000000000000003
First registered
Last updated
Status
In development
Trial dates
2020-12-15 – 2022-01-15
Countries
Private
JEL codes
I18, H75
Registry record
http://www.socialscienceregistry.org/trials/6602

Abstract

Despite an enormous policy response, opioid prescribing remains well above historical levels and harms from opioids continue to mount. Nearly all states have Prescription Monitoring Programs (PMPs) to facilitate safer prescribing of opioids and other drugs, but research suggests these systems only deliver benefits when health care professionals are required to use them. Even with PMP mandates in place, providers may be unaware of the dangers of co-prescribing opioids with benzodiazepines or gabapentinoids, which include increased risk of overdose and death. Working with the Minnesota state government, we will mail letters to guideline-discordant opioid prescribers that either highlight an upcoming legally mandated requirement to check the PMP before prescribing an opioid, inform and educate providers about their patients filling concurrent prescriptions and the dangers of such co-prescribing, or both. Study participants will be randomized to receive no intervention or one of the three treatment letters. Using administrative data, we will track effects of the letters on not only prescribing but also PMP usage and queries. Findings form the multiplicity of treatment messages and outcomes will shed light on the mechanisms driving overprescribing. Results will inform future work by state and local policymakers to make opioid prescribing safer.

Intervention

Prescribers will be assigned at random to one of four arms:
1. PMP Use Mandate Letter: Prescribers are sent letters with reminders about the mandate to check the PMP when prescribing opioids.
2. Prescribing Information Letter: Prescribers are sent letters with information about their patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
3. Prescribing Information + PMP Use Mandate Letter: Prescribers are sent letters combining the content in arms 1 and 2, reminding them about the PMP use mandate and providing information about their patients who received co-prescriptions.
4. Control (As Usual / No Letter): These prescribers are not sent letters, the as-usual case.

Experimental design

At the start of the study, we will conduct a review of PMP records to identify prescribers who wrote opioid-benzodiazepine and opioid-gabapentinoid co-prescriptions. Prescribers will be randomized at 1:1:1:1 ratio to one of three treatment arms or a control arm. Then prescribers in the treatment arms will be sent two letters, one month apart.

Design details

Randomization method
Stratified randomization done using random numbers generated in Stata
Randomization unit
Prescriber
Clusters
12,000 prescribers
Observations
12,000 prescribers
Arms
3,000 prescribers per arm
Primary outcomes
1. Number of patients with co-prescriptions during the 60 days after letters were sent 2. Indicator for checking the PMP during the 60 days after letters were sent
Sponsors
Name: Abdul Latif Jameel Poverty Action Lab (J-PAL) Location: Cambridge, MA Url: https://www.povertyactionlab.org
Partners
Name: Minnesota Management and Budget Agency Partner_type: government Url: https://mn.gov/mmb/ Name: Minnesota Board of Pharmacy Partner_type: government Url: https://mn.gov/boards/pharmacy/

Cited by

No citation data available for this registration yet.

Keywords